©2022 Stanford Medicine
Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies
Not Recruiting
Trial ID: NCT00186342
Purpose
The purpose of this study is to determine the tolerability and efficacy in treating patients
aged 51-60 with acute leukemia and in treating myelodysplastic syndromes (MDS) or
myeloproliferative disorders (MPD).
Official Title
Allogeneic Sibling and Unrelated Donor Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Busulfan, Etoposide and Cyclophosphamide
Stanford Investigator(s)
Robert Negrin
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Laura Johnston
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Eligibility
Inclusion Criteria:1) Patients aged 51-60 with acute non-lymphocytic leukemia in first or
subsequent remission and acute lymphocytic leukemia in first remission with high risk
features which include elevated white blood cell count at presentation, cytogenetic
abnormalities, extramedullary leukemia, ALL in greater than first remission and patients
with chronic myelogenous leukemia at any stage who have a histocompatible sibling donor.
2) Patients with myelodysplastic syndrome including patients with refractory anemia with
excess blasts or refractory anemia with excess blasts in transformation.
3) Patients with myeloproliferative disorders which give them poor long-term disease-free
survival, such as myeloid metaplasia or myeloid fibrosis.
4) Patients with secondary myelodysplasia following cytotoxic chemotherapy. Exclusion
Criteria:- Organ dysfunction
Intervention(s):
procedure: ablative allogeneic hematopoietic cell transplantation
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
BMT Referrals
6507230822